Market Performance Summary for Gilead Sciences, Inc. (February 16, 2026)
On February 16, 2026, Gilead Sciences, Inc. (NASDAQ: GILD) exhibited a positive performance in the U.S. stock market. The stock opened at $151.89 and closed at $154.98, marking an increase of $3.17 or 2.09% compared to the previous close of $151.81. Throughout the trading day, the stock fluctuated between a low of $151.46 and a high of $156.95. Trading volume was approximately 6.86 million shares. As of this date, Gilead’s market capitalization stood at approximately $192.28 billion.
Key Financial Results
- Revenue Growth: For the fourth quarter of 2025, revenues rose by 5% to $7.9 billion compared to the same quarter in 2024. Full-year revenues increased by 2% to $29.4 billion.
- Product Sales: Excluding sales of Veklury (Gilead’s COVID-19 treatment), full-year product sales totaled $28.0 billion, representing a 4% increase. HIV product sales grew by 6% to $20.8 billion, with Biktarvy sales rising 7% to $14.3 billion.
- Earnings Per Share (EPS): Diluted EPS in Q4 2025 was $1.74, up from $1.42 in Q4 2024. The full-year EPS substantially increased to $6.78 compared to $0.38 in 2024.
- Operating Expenses: Research and Development (R&D) expenses remained steady at $1.6 billion for Q4 2025. Selling, General and Administrative (SG&A) expenses declined from $1.9 billion to $1.8 billion year-over-year.
- Cash Flow: Operating cash flow reached $3.3 billion in Q4 2025. Dividends paid amounted to $1.0 billion, alongside a common stock repurchase totaling $230 million.
Strategic Outlook for 2026
Gilead Sciences has issued financial guidance for the year 2026, projecting product sales between $29.6 billion and $30.0 billion. The company expects diluted EPS to range between $6.75 and $7.15. Growth is anticipated to be driven by new product launches such as Yeztugo, an HIV prevention therapy, along with upcoming cancer therapies. Additionally, positive outcomes from Phase 3 clinical trials for new HIV treatments are expected to further support the company’s performance.
Recent Announcements
- Dividend Increase: Gilead declared a 3.8% increase in its first-quarter dividend for 2026, signaling financial stability and confidence in future growth.
- FDA Approval: The company received FDA approval for a label update for Yescarta®, which is indicated for the treatment of relapsed/refractory primary central nervous system lymphoma, thereby strengthening Gilead’s oncology portfolio.
Market Impact
The positive financial results, combined with strategic product introductions and regulatory progress, have contributed to an optimistic market sentiment toward Gilead Sciences. The stock’s upward movement on February 16, 2026, reflects investor confidence in the company’s growth potential and future trajectory.
Conclusion
Gilead Sciences, Inc. has demonstrated resilience and growth in its financial metrics for the year 2025, complemented by a strong outlook for 2026. The company’s ability to expand product sales, maintain operational efficiency, and secure regulatory approvals underpins this positive performance. The market’s reaction today aligns with these solid fundamentals and strategic advancements. Additional detailed financial information and official press releases can be found on Gilead’s Investor Relations website.
Explore more exclusive insights at nextfin.ai.
